Increased gut permeability and bacterial translocation are associated with fibromyalgia and myalgic encephalomyelitis/chronic fatigue syndrome: implications for disease-related biomarker discovery.
anti-beta-lactoglobulin
chronic fatigue syndrome
fibromyalgia
intestinal permeability
myalgic encephalomyelitis
zonulin
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
04
07
2023
accepted:
25
08
2023
medline:
26
9
2023
pubmed:
25
9
2023
entrez:
25
9
2023
Statut:
epublish
Résumé
There is growing evidence of the significance of gastrointestinal complaints in the impairment of the intestinal mucosal barrier function and inflammation in fibromyalgia (FM) and in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). However, data on intestinal permeability and gut barrier dysfunction in FM and ME/CFS are still limited with conflicting results. This study aimed to assess circulating biomarkers potentially related to intestinal barrier dysfunction and bacterial translocation and their association with self-reported symptoms in these conditions. A pilot multicenter, cross-sectional cohort study with consecutive enrolment of 22 patients with FM, 30 with ME/CFS and 26 matched healthy controls. Plasma levels of anti-beta-lactoglobulin antibodies (IgG anti-β-LGB), zonulin-1 (ZO-1), lipopolysaccharides (LPS), soluble CD14 (sCD14) and interleukin-1-beta (IL-1β) were assayed using ELISA. Demographic and clinical characteristics of the participants were recorded using validated self-reported outcome measures. The diagnostic accuracy of each biomarker was assessed using the receiver operating characteristic (ROC) curve analysis. FM patients had significantly higher levels of anti-β-LGB, ZO-1, LPS, and sCD14 than healthy controls (all Biomarkers of intestinal barrier function and inflammation were associated with autonomic dysfunction assessed by COMPASS-31 scores in FM and ME/CFS respectively. Anti-β-LGB antibodies, ZO-1, LPS, and sCD14 may be putative predictors of intestinal barrier dysfunction in these cohorts. Further studies are needed to assess whether these findings are causal and can therefore be applied in clinical practice.
Sections du résumé
Background
There is growing evidence of the significance of gastrointestinal complaints in the impairment of the intestinal mucosal barrier function and inflammation in fibromyalgia (FM) and in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). However, data on intestinal permeability and gut barrier dysfunction in FM and ME/CFS are still limited with conflicting results. This study aimed to assess circulating biomarkers potentially related to intestinal barrier dysfunction and bacterial translocation and their association with self-reported symptoms in these conditions.
Methods
A pilot multicenter, cross-sectional cohort study with consecutive enrolment of 22 patients with FM, 30 with ME/CFS and 26 matched healthy controls. Plasma levels of anti-beta-lactoglobulin antibodies (IgG anti-β-LGB), zonulin-1 (ZO-1), lipopolysaccharides (LPS), soluble CD14 (sCD14) and interleukin-1-beta (IL-1β) were assayed using ELISA. Demographic and clinical characteristics of the participants were recorded using validated self-reported outcome measures. The diagnostic accuracy of each biomarker was assessed using the receiver operating characteristic (ROC) curve analysis.
Results
FM patients had significantly higher levels of anti-β-LGB, ZO-1, LPS, and sCD14 than healthy controls (all
Conclusion
Biomarkers of intestinal barrier function and inflammation were associated with autonomic dysfunction assessed by COMPASS-31 scores in FM and ME/CFS respectively. Anti-β-LGB antibodies, ZO-1, LPS, and sCD14 may be putative predictors of intestinal barrier dysfunction in these cohorts. Further studies are needed to assess whether these findings are causal and can therefore be applied in clinical practice.
Identifiants
pubmed: 37744357
doi: 10.3389/fimmu.2023.1253121
pmc: PMC10512706
doi:
Substances chimiques
Lipopolysaccharide Receptors
0
Lipopolysaccharides
0
Types de publication
Multicenter Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1253121Informations de copyright
Copyright © 2023 Martín, Blanco-Suárez, Zambrano, Cáceres, Almirall, Alegre-Martín, Lobo, González-Castro, Santos, Domingo, Jurek and Castro-Marrero.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
CNS Neurol Disord Drug Targets. 2023;22(2):215-225
pubmed: 35946099
Brain Behav Immun Health. 2023 Apr 27;30:100627
pubmed: 37396339
Psychiatry Res. 1989 May;28(2):193-213
pubmed: 2748771
Medicina (Kaunas). 2021 Apr 16;57(4):
pubmed: 33923830
J Clin Med. 2021 Jul 06;10(14):
pubmed: 34300183
Med Hypotheses. 2020 Feb 26;140:109648
pubmed: 32126475
Metabolomics. 2019 Mar 27;15(4):54
pubmed: 30919098
J Clin Med. 2016 Jun 06;5(6):
pubmed: 27275835
Clin Rheumatol. 1997 Jan;16(1):9-12
pubmed: 9132333
Cell Host Microbe. 2023 Feb 8;31(2):288-304.e8
pubmed: 36758522
Clin Exp Rheumatol. 2022 Jun;40(6):1065-1072
pubmed: 35748720
Curr Top Med Chem. 2018;18(19):1641-1655
pubmed: 30430944
In Vivo. 2013 Mar-Apr;27(2):177-87
pubmed: 23422476
Front Immunol. 2019 Apr 16;10:796
pubmed: 31057538
Clin Infect Dis. 1994 Jan;18 Suppl 1:S79-83
pubmed: 8148458
Int J Mol Sci. 2023 Mar 07;24(6):
pubmed: 36982194
PLoS One. 2015 Dec 18;10(12):e0145453
pubmed: 26683192
Mol Neurobiol. 2014 Apr;49(2):741-56
pubmed: 24068616
Clin Ther. 2019 Apr;41(4):612-618
pubmed: 30795933
Front Med (Lausanne). 2021 Jan 18;7:606824
pubmed: 33537329
Br J Pain. 2021 Feb;15(1):26-39
pubmed: 33633851
Adv Clin Chem. 2014;66:121-72
pubmed: 25344988
Neuro Endocrinol Lett. 2007 Dec;28(6):739-44
pubmed: 18063928
Semin Arthritis Rheum. 2022 Oct;56:152060
pubmed: 35849890
Nutr Metab (Lond). 2010 Oct 12;7:79
pubmed: 20939923
Clin Exp Rheumatol. 2020 Jan-Feb;38 Suppl 123(1):99-104
pubmed: 32116215
Microbiome. 2017 Apr 26;5(1):44
pubmed: 28441964
Sci Rep. 2018 Jul 3;8(1):10056
pubmed: 29968805
Ann Rheum Dis. 2004 Apr;63(4):450-2
pubmed: 15020342
Med Clin (Barc). 1995 May 27;104(20):771-6
pubmed: 7783470
Curr Pharm Des. 2016;22(40):6058-6075
pubmed: 27634186
Pain. 2019 Nov;160(11):2589-2602
pubmed: 31219947
Arthritis Care Res (Hoboken). 2010 May;62(5):600-10
pubmed: 20461783
Biomedicines. 2023 Jun 13;11(6):
pubmed: 37371796
Metab Brain Dis. 2019 Apr;34(2):385-415
pubmed: 30758706
J Affect Disord. 2007 Apr;99(1-3):237-40
pubmed: 17007934
J Intern Med. 2011 Oct;270(4):327-38
pubmed: 21777306
Medicina (Kaunas). 2021 May 19;57(5):
pubmed: 34069603
Mayo Clin Proc. 2012 Dec;87(12):1196-201
pubmed: 23218087
BMC Musculoskelet Disord. 2023 Feb 27;24(1):150
pubmed: 36849949
BMC Neurol. 2017 May 11;17(1):88
pubmed: 28490352
J Clin Med. 2021 Oct 29;10(21):
pubmed: 34768601
Cureus. 2022 Oct 4;14(10):e29923
pubmed: 36381861
Neuro Endocrinol Lett. 2008 Dec;29(6):902-10
pubmed: 19112401
Acta Paediatr. 2016 Sep;105(9):e412-8
pubmed: 27177188
In Vivo. 2009 Jul-Aug;23(4):621-8
pubmed: 19567398
Rheumatology (Oxford). 2008 Aug;47(8):1223-7
pubmed: 18540025
Neuro Endocrinol Lett. 2015;36(5):439-46
pubmed: 26707044
Microbiome. 2016 Jun 23;4(1):30
pubmed: 27338587
BMC Musculoskelet Disord. 2020 Mar 20;21(1):181
pubmed: 32192466
Neurogastroenterol Motil. 2023 Apr;35(4):e14546
pubmed: 36807964
J Transl Med. 2018 Nov 21;16(1):322
pubmed: 30463572
Curr Opin Gastroenterol. 2008 Jan;24(1):11-6
pubmed: 18043226
Front Immunol. 2022 Jan 03;12:628741
pubmed: 35046929
Mol Psychiatry. 2022 Jan;27(1):141-153
pubmed: 33558650